Weight-loss surgery for treating type 2 diabetes
The healthcare industry’s most distinguished leaders will come together this November for Cleveland Clinic’s 2010 Medical Innovation Summit. Their focus? Obesity, diabetes and the metabolic crisis.
Such is the increasing attention paid to the link between obesity and type 2 diabetes. More than half of Americans are overweight, and roughly 12 million Americans have severe obesity (defined as being 100 pounds or more overweight). Obesity is one of the most important factors in the development of type 2 diabetes.
Studies have shown that bariatric surgery (also known as gastric bypass or weight-loss surgery) is an effective tool not only for treating obesity but for preventing, treating and even resolving diabetes in some cases.
The Bariatric and Metabolic Institute works closely with Cleveland Clinic’s Endocrinology & Metabolism Institute to treat patients with diabetes and develop a program tailored to suit their needs.
Plans are in the works for an even closer collaboration. With philanthropic support, Cleveland Clinic aims to establish an innovative, world-class Obesity Center to be headed by Philip Schauer, MD, Director of the Bariatric and Metabolic Institute. Dr. Schauer, who has an international reputation for innovation and excellence in gastric bypass surgeries, heads the ongoing STAMPEDE study.
STAMPEDE (Surgical Therapy and Medications Potentially Eradicate Diabetes Efficiently) is a randomized study that will compare the effectiveness of advanced medical therapy alone versus bariatric surgery and therapy combined, for the treatment of type 2 diabetes during a five-year study period. The clinical trial is currently recruiting participants.
To make a gift supporting the Obesity Center, the Endocrinology & Metabolism Institute, the Bariatric and Metabolic Institute or any area of Cleveland Clinic, visit our secure online giving site, or call Institutional Relations and Development at 216.444.1245 or toll-free at 800.223.2273, ext. 41245.